青年医者是医学传承与创新的中坚力量,他们既怀揣专业热忱,又善于用鲜活视角链接大众。2月4日 12:00,《医线零距离》首期栏目邀请山东大学齐鲁医院胃癌MDT团队的青年骨干,跟随消化内科、胃肠外 科、放射科、病理科、肿瘤内科的青年医者们,走进一线,揭秘胃癌诊疗背后的协作密码。 健康直播栏目《医线零距离》由齐鲁晚报·齐鲁壹点与山东大学齐鲁医院团委联合打造,通过走进各临床 一线科室,与青年医者面对面,向大众科普医学健康知识。 今年2月4日是第27个"世界癌症日",主题为"以人为本,携手抗癌"。胃癌作为我国高发肿瘤之一,早期筛查 与规范诊疗是提升治愈率的关键,其中多学科协作(MDT)正是应对胃癌的高效诊疗模式。 ◆医线零距离 ...

科室简介 作为市卫健局和教体局授牌的"青少年低视力防治中心"和威海唯一一家"中国近视防控能力建设联盟"骨 干级单位,拥有眼视光研究生验光师1人,眼视光本科验光师1人,检查技师4人,同时依托眼科门诊专业医师 给予鉴别真假性近视、眼科疾病造成的视力下降等问题,针对相应问题给予专业解答。 眼视光门诊占地面积300平方米,设有验光室2间、角膜接触镜验配室2间、训练室1间、检查室3间、加工 室和柜台展览区。配有日本拓普康综合验光仪和尼德克综合验光仪、德国蔡司眼底扫描仪、日本佳能光 学相干断层血管成像扫描仪、德国蔡司IOLMaster700眼生物测量仪,配有视觉训练系统、法国依视路全 自动磨边机、扫描仪、数码裂隙灯、角膜地形图、角膜内皮计数仪等设备。 乳山市人民医院眼视光门诊地点:门诊医技楼三楼眼科门诊。 寒假是儿童青少年视力养护的关键时期,也是验光配镜的高峰期。为满足广大家庭对专业视光服务的需 求,乳山市人民医院眼视光中心于即日起推出"暖心护眼·寒假惠民"专项活动:活动期间,凡在该中心配镜, 均可享受全场8折优惠,范围涵盖国产与进口光学镜片、儿童青少年功能型镜片等多种产品。 专业验光,科学配镜,用实惠价格给孩子贴心守护 ...

为保障患者安全,心内一科第一时间联系肾病科、ICU等科室开展多学科会诊。经过综合研判,专家团队 决定将周大姨转入ICU病房,实施连续性床旁血液净化治疗,同时严密监测心功能变化。 经过精心治疗,周大姨的心衰症状明显改善,生命体征逐渐平稳,顺利转回普通病房继续治疗。 这场跨越急诊科、心内科、ICU、肾病科、介入中心等多个科室的救治,正是荣成市人民医院多学科协作 (MDT)模式的生动实践,通过整合优质医疗资源,打破学科壁垒,为危重患者搭建起高效、精准的救治通道, 最大限度保障了患者的术前、术中、术后安全。 (李煜) 近日,64岁的周大姨(化名)在荣成市人民医院康复出院,想起这段惊心动魄的救治经历,她和家人满怀感激, 连连向医护人员致谢。 2025年11月中旬的一个凌晨,睡梦中的周大姨突然被剧烈的胸痛惊醒,疼痛持续不缓解,家人见状就近将她 送往荣成市中医院。心电图检查提示心肌酶谱、心衰指标均显著增高,情况危急。荣成市中医院立即启 动荣成胸痛中心联盟救治流程,120急救车火速将周大姨转诊至荣成市人民医院急诊科。 作为荣成胸痛中心联盟的核心单位,荣成市人民医院对高危胸痛患者的救治早已形成成熟的快速响应机 制。急诊科与心内 ...

1月19日清晨,寒风裹挟着凛冽寒意呼啸而过,而在荣成市人民医院内,却涌动着一股跨越严寒的暖流—— 威海市中心血站流动采血车缓缓驶入,一场以热血赴使命、以爱心暖寒冬的无偿献血活动,在此温情启 幕。百名医护人员主动放下手头忙碌的工作,有序集结、挽袖献爱,用滚烫的热血为这个寒冬注入温暖力 量,用实际行动诠释医者仁心的担当。 (李煜) 从登记信息、测量血压、血液初筛到最终献血,每一个环节都有条不紊地推进。采血车旁,既有工龄数十 年、坚持多年献血的"爱心老兵",他们用一沓厚厚的献血证,默默见证着数十载传递大爱的坚持；也有初 登献血车的年轻医护,在前辈的感召下迈出公益第一步,用青春热血书写责任担当。 凛冽寒风中,白大褂与献血车的红色标识交相辉映,成为这个冬日里最动人的风景。当带着体温的血液缓 缓流入采血袋,便完成了一场从医者到患者的生命接力。这不仅是一袋袋血液的传递,更是一份份医者初 心的传承。 ...

为持续提升团队专业能力,科室建立了完善的学习培训体系:定期安排医护人员赴国内知名医院进修深造, 紧跟行业前沿技术与诊疗理念；常态化开展核心制度、诊疗规范、临床指南等专题培训,夯实诊疗基 础；积极推行"师带徒"机制,让高年资医师的临床经验与技术专长在传帮带中得以传承,助力青年医师快 速成长,打造出一支"召之即来、来之能战"的专业队伍。 (李煜) 病区开设床位90张,充分满足区域患者就医需求。同时,打造了威海市范围内唯一的呼吸重症监护室 (RICU),凭借专属诊疗空间与尖端设备,集中力量开展危重症患者救治,显著提高了呼吸衰竭、重症肺炎等 急危重症的抢救成功率,成为守护患者生命的"最后一道防线"。 科室始终坚持"引育并举、梯队建设"的人才战略,构建起一支结构合理、技术精湛、富有活力的医护团 队。目前科室拥有医师14人,其中硕士研究生及高级职称人员占比均达1/3以上,形成了"高学历、高职称 引领,中青年骨干支撑"的良好格局。 自2005年荣成市人民医院呼吸与危重症医学科成立以来,历经十八载深耕细作、砥砺前行,从青涩起步到 跻身地区领先,用精湛医术与暖心服务,为无数呼吸系统疾病患者筑起生命防线。 2020年10月,顺利 ...

2026年上海市政府工作报告将"加快建设免陪护照护服务体系""深化多元复合医保支付方式改革，加强创新药和医 疗器械推广应用"等作为2026年的主要任务。 "此次我的发言建议是'免陪照护服务'背后的专业人才岗位和体系打造。"2026年上海两会召开期间，2月3日下 午，在上海市政协十四届四次会议一场医卫界别分组会议（下称"分组会议"）上，上海市政协常委、复旦大学附 属中山医院（下称"中山医院"）副院长钱菊英表示，随着老龄化进程加速，"免陪照护服务"能在未来进一步减轻 独生子女负担，"目前，我院平均每天会为1300至1400位病人开设此项服务，但具备对应技能的护理人员较为缺 乏、受教育程度普遍不高、劳动关系较为分散，这些问题亟需引起重视"。 "'药'的创新、转化与应用，不但关乎民众生命健康，也是上海'十五五'规划建议中促进生物医药高端高效发展的 核心任务所在。"上海市政协委员、上海交大系统生物医学教育部重点实验室主任韩泽广在分组会议上如是说，生 物医药领域的创新，则需要"产学研用"全链条足够顺畅。 上述委员们对于卫生健康、生物医药领域的建言，不但能为大众关心的民生事项提供"纾解"，也正为政策制定"前 置"提供进一步 ...

Group 1 - The core viewpoint of the news is that Langma Information (300288) has experienced a decline in its financial performance, with significant drops in revenue and net profit for the first three quarters of 2025 compared to the previous year [2] - As of February 3, 2026, Langma Information's stock closed at 14.57 yuan, up 2.17%, with a turnover rate of 3.88% and a trading volume of 99,500 hands, resulting in a transaction amount of 143 million yuan [1] - The net outflow of main funds on February 3 was 2.0659 million yuan, accounting for 1.44% of the total transaction amount, while retail investors saw a net inflow of 7.6134 million yuan, representing 5.31% of the total transaction amount [1] Group 2 - For the first three quarters of 2025, Langma Information reported a main operating income of 224 million yuan, a year-on-year decrease of 24.75%, and a net profit attributable to shareholders of 13.507 million yuan, down 67.04% year-on-year [2] - In the third quarter of 2025 alone, the company recorded a single-quarter main operating income of 72.5269 million yuan, a decline of 36.46% year-on-year, and a net profit attributable to shareholders of -0.9285 million yuan, reflecting a decrease of 105.48% year-on-year [2] - The company's debt ratio stands at 17.27%, with investment income of 16.9959 million yuan and a gross profit margin of 29.25% [2]

《每日经济新闻》记者注意到，从陪诊服务吸引海外散客，到海外华侨"用脚投票"回国就医，再到国内 医院系统化布局国际医疗中心，一幅中国医疗服务"反向出海"的图景正在展开。高效的诊疗流程、高超 的医术、相对亲民的价格以及日益国际化的服务标准，让中国成为越来越多全球患者的新选择。 "我看到你的陪诊笔记，决定飞来上海！"2025年底，当陪诊师赵洋（化名）收到这条来自美国的私信咨 询时，她未曾想到，一单看似普通的陪诊业务，会成为中国医疗服务吸引力辐射国外的生动注脚。因在 美国预约一项肠道检测需等待两个月，这位名叫Malka的美国患者，最终选择跨越太平洋，来到中国求 医。 无独有偶，远在东南亚创业的海外华侨马伟民，在遭遇当地医院误诊和高昂医疗费用后，也毅然买下机 票，连夜回国接受手术治疗。他直言，与海外繁琐的分级诊疗和漫长等待相比，国内医疗效率、水平均 相当高，更值得信任。 Malka被肠胀气等问题困扰多年，在美国，医生建议她进行SIBO（小肠细菌过度生长）检测，但预约排 到两个月后。焦急的她，无意间在社交平台上看到陪诊师赵洋分享的上海交通大学医学院附属仁济医院 （以下简称仁济医院）SIBO检查流程笔记。考虑到仁济医院在消 ...

Core Viewpoint - Fosun Pharma is leveraging AI technology to enhance drug development and healthcare services, focusing on integrating AI into various stages of the pharmaceutical process to improve efficiency and decision-making capabilities [10]. Group 1: Investment in AI for Drug Development - Fosun Pharma's subsidiary, Fuhong Hanlin, is collaborating with DeepMind Technology to address early-stage drug development challenges by integrating AI and physical modeling techniques [3]. - The company has developed the PharmAID decision-making platform, which utilizes advanced language models to enhance the accuracy of drug development processes by 50% compared to traditional models [4][5]. Group 2: Implementation of AI Across R&D Processes - Fosun Pharma has established an internal AI project management mechanism that focuses on real-world applications, aiming to quantify value through metrics such as efficiency improvement and cost reduction [6]. - The company is promoting AI tools in critical areas such as clinical writing and patent analysis, creating a positive feedback loop between technology adaptation and iterative improvements [6]. Group 3: AI Applications in Other Business Segments - Fosun Pharma's subsidiary, Fosun Xingmai, has developed over 70 AI products in pathology, ultrasound, and radiology, achieving widespread clinical application and recognition in international competitions [8]. - The company is optimizing marketing and operational efficiency through AI, including intelligent training for sales personnel and significant cost reductions in document translation [9]. Group 4: Industry Leadership and Future Outlook - Fosun Pharma's approach serves as a model for the pharmaceutical industry, combining in-house development with external collaboration to balance technological autonomy and implementation efficiency [10]. - The company plans to further integrate AI into digital clinical trials and organoid experiments, expanding the application of AI in healthcare and continuing to lead the industry's transformation [11].

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Tongce Medical (600763), indicating a positive trend in both stock price and financial results [1][2] - As of February 3, 2026, Tongce Medical's stock closed at 48.26 yuan, reflecting a 2.25% increase with a trading volume of 170,400 hands and a total transaction amount of 818 million yuan [1] - In terms of capital flow on February 3, 2026, the net inflow of main funds was 44.53 million yuan, accounting for 5.44% of the total transaction amount, while retail investors experienced a net outflow of 2.59 million yuan, representing 0.32% of the total [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The third quarter of 2025 saw a single-quarter main revenue of 842 million yuan, reflecting a 2.34% year-on-year increase, with a net profit of 192 million yuan, up 2.31% year-on-year [2] - The company has a debt ratio of 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, alongside a gross profit margin of 41.69% [2] Group 3 - Over the past 90 days, five institutions have provided ratings for Tongce Medical, with three giving a "buy" rating and two an "increase" rating, while the average target price set by institutions is 51.1 yuan [2]